Last reviewed · How we verify
SB-240563
At a glance
| Generic name | SB-240563 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab) (PHASE4)
- Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
- NUCALA® Special Drug Use Investigation (EGPA, Long-term)
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (PHASE3)
- Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
- Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease (PHASE2)
- Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA (PHASE4)
- The Role of IL5 in Epithelial Cell Integrity (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB-240563 CI brief — competitive landscape report
- SB-240563 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI